Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Amryt Announces EMA’s COMP Has Adopted Positive Opinion On Orphan Disease Designation For Mycapssa For Acromegaly
Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the European Medicines
Amry Announced CHMP Adopts Positive Opinion for Mycapssa for the Treatment of Acromegaly
Amryt (Nasdaq: AMYT) is pleased to announce that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Mycapssa® in the European Union (EU) for the maintenance treatment of acromegaly in patients who have responded to and to
Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for…
Amryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder Candidate
The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorisation Approval (MAA) and Orphan Disease Designation (ODD) for Amryt’s (NASDAQ: AMYT) lead candidate Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in
Amryt Receives Marketing Authorisation Approval And Orphan Drug Designation For Filsuvez In Great Britain
Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Medical Healthcare &
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Amryt Receives Orphan Drug Designation From The FDA For Mycapssa For The Treatment Of Carcinoid Syndrome
Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that the US Food and Drug
Filsuvez’s European Approval Adds Growth Driver For Amryt Pharma
Yesterday, Amryt Pharma plc (NASDAQ:AMYT) received European approval for Filsuvez for partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB)…
SVB Leerink Maintains Outperform on Amryt Pharma, Raises Price Target to $19
SVB Leerink analyst Mani Foroohar maintains Amryt Pharma (NASDAQ:AMYT) with a Outperform and raises the price target from $18 to $19.